Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
The seller seems to have gone for the moment. Nice consolidation going on at 60p. Maybe at this level we'll have the new launch pad off which the SP will be launched into new heights on the basis that there's a nice update tomorrow.
It will be a surprise if the AGM goes past without some kind of update. A refresher is due soon, so must be a good chance it is available tomorrow.
Is Tiziana's drug to be expedited too by FED in a similar way to the one from 4D Pharma has been by UK's MHRA? If so, I'm jumping on the boat as I think it has great potential.
Setting aside a director purchase on March 18 and unlike Tiziana, 4D was moving under the radar and announced on April 20 that its drug, MRx-4DP0004, was expedited by MHRA to commence Phase II trials.
I'm posting on this board as the drug also addresses hyper inflammation and it is orally administered:
" 4D pharma’s Live Biotherapeutic MRx-4DP0004 is the first immunomodulatory therapy being tested in patients hospitalised with COVID-19 which has shown the potential to simultaneously down-regulate specific pathological aspects of the hyper-inflammatory response while maintaining the appropriate anti-viral response "
4D’s RNS, 20 April 20
Tiziana you’re in the spotlight now.
Would a drug with any real potential against coronavirus be worth 120k US dollars plus 600k upon milestones?
From last Friday's RNS:
"Recent studies have also suggested that Act D, being a potent inhibitor of RNA synthesis, may have potential for treatment of COVID-19 patients (4) "
They are quoting reference (4) which dates back to 1978. Are we talking about the same or comparable strain to coronavirus?
4. Kennedy, D.A., and Johnson-Lussenburg (1978). Inhibition of Coronavirus 229E Replication by Actinomycin D JOURNAL OF VIROLOGY, Jan. 1978, p. 401-404.
Then we are looking at a "hypothesis" using the word from the RNS earlier today that it will work alongside TZLS-501.
Results show that the Sanofi drug is only benefiting patients at a very advanced stage and with severe symptoms who are in need of oxygen supply.
Time to test the hypothesis.
'Sometimes the first duty of intelligent men is the restatement of the obvious.' George Orwell
Thank you JohnHenry. Do we know whether they are even talking to the FDA?
The floor of 45-50p is probably because of the funding.
Have been watching Tiziana with interest for some time now.
Since the March RNS there is the filing of a patent and the funding but we can only guess what the company is working on.
I'm thinking of taking a punt especially now that the price seems good but isn't time running out for Tiziana at least for its covid drug? There is full visibility on the timing of the other drugs such as Acterma but nothing from Tiziana. From my experience when you wait a long time for the transformational news, they rarely happen.
What do people think? Does Tiziana have a plan and why does it take the company a long time to disclose?
Whatever the tidying up, the company will only be noticed by rivals when it starts the trials and results start to come in.